Butler DC - Search Results

1

Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.

Butler DC, Joshi SN, Genst E, Baghel AS, Dobson CM, Messer A. Butler DC, et al. PLoS One. 2016 Nov 8;11(11):e0165964. doi: 10.1371/journal.pone.0165964. eCollection 2016. PLoS One. 2016. PMID: 27824888 Free PMC article.

2

Developing intrabodies for the therapeutic suppression of neurodegenerative pathology.

Messer A, Lynch SM, Butler DC. Messer A, et al. Among authors: butler dc. Expert Opin Biol Ther. 2009 Sep;9(9):1189-97. doi: 10.1517/14712590903176387. Expert Opin Biol Ther. 2009. PMID: 19653865 Review.

3

Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Butler DC, McLear JA, Messer A. Butler DC, et al. Prog Neurobiol. 2012 May;97(2):190-204. doi: 10.1016/j.pneurobio.2011.11.004. Epub 2011 Nov 18. Prog Neurobiol. 2012. PMID: 22120646 Free PMC article. Review.

4

Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.

Butler DC, Messer A. Butler DC, et al. PLoS One. 2011;6(12):e29199. doi: 10.1371/journal.pone.0029199. Epub 2011 Dec 22. PLoS One. 2011. PMID: 22216210 Free PMC article.

5

Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies.

Joshi SN, Butler DC, Messer A. Joshi SN, et al. Among authors: butler dc. MAbs. 2012 Nov-Dec;4(6):686-93. doi: 10.4161/mabs.21696. Epub 2012 Aug 28. MAbs. 2012. PMID: 22929188 Free PMC article.

6

Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease.

Butler DC, Snyder-Keller A, De Genst E, Messer A. Butler DC, et al. Protein Eng Des Sel. 2014 Oct;27(10):359-63. doi: 10.1093/protein/gzu041. Protein Eng Des Sel. 2014. PMID: 25301961 Free PMC article.

7

Structure of a single-chain Fv bound to the 17 N-terminal residues of huntingtin provides insights into pathogenic amyloid formation and suppression.

De Genst E, Chirgadze DY, Klein FA, Butler DC, Matak-Vinković D, Trottier Y, Huston JS, Messer A, Dobson CM. De Genst E, et al. Among authors: butler dc. J Mol Biol. 2015 Jun 19;427(12):2166-78. doi: 10.1016/j.jmb.2015.03.021. Epub 2015 Apr 8. J Mol Biol. 2015. PMID: 25861763 Free PMC article.

8

Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model.

Chatterjee D, Bhatt M, Butler D, De Genst E, Dobson CM, Messer A, Kordower JH. Chatterjee D, et al. NPJ Parkinsons Dis. 2018 Aug 22;4:25. doi: 10.1038/s41531-018-0062-4. eCollection 2018. NPJ Parkinsons Dis. 2018. PMID: 30155513 Free PMC article.

9

Computational affinity maturation of camelid single-domain intrabodies against the nonamyloid component of alpha-synuclein.

Mahajan SP, Meksiriporn B, Waraho-Zhmayev D, Weyant KB, Kocer I, Butler DC, Messer A, Escobedo FA, DeLisa MP. Mahajan SP, et al. Among authors: butler dc. Sci Rep. 2018 Dec 4;8(1):17611. doi: 10.1038/s41598-018-35464-7. Sci Rep. 2018. PMID: 30514850 Free PMC article.

10

Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders.

Messer A, Butler DC. Messer A, et al. Among authors: butler dc. Neurobiol Dis. 2020 Feb;134:104619. doi: 10.1016/j.nbd.2019.104619. Epub 2019 Oct 25. Neurobiol Dis. 2020. PMID: 31669671 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90 results

Search Page

Filters